Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphoma

Blood Adv. 2021 Sep 28;5(18):3563-3567. doi: 10.1182/bloodadvances.2021004880.
No abstract available

MeSH terms

  • Adult
  • Antigens, CD19
  • Biological Products
  • Humans
  • Immunotherapy, Adoptive*
  • Lymphoma, B-Cell* / drug therapy
  • Lymphoma, B-Cell* / epidemiology

Substances

  • Antigens, CD19
  • Biological Products
  • axicabtagene ciloleucel